European Lead Factory one of IMI’s most high-profile projects

21 December 2017

Until now, the Innovative Medicines Initiative (IMI) has launched almost 100 projects to tackle the barriers that currently limit the efficiency, effectiveness and quality of medical research and drug development. 

The December issue of IMI’s European Files focuses on public private partnerships to strengthen innovation research in Europe. In this issue, Pierre Meulien, Executive Director of IMI, describes the European Lead Factory (ELF) as “one of IMI’s most high-profile projects delivering resources for the scientific community”. ELF’s Joint European Compound Library contains over 500.000 compounds, coming from 7 EFPIA partners and the project’s own synthetic chemistry programme.

In the words of Pierre Meulien, IMI Executive Director, is ELF “one of IMI-JU’s most high-profile projects delivering resources for the scientific community”. 

By December 2017, ELF has run 72 screens for public partners, including 14 small and medium-sized enterprises (SMEs), and covering disease areas such as antimicrobial resistance, Alzheimer’s disease, diabetes, cancer, and neglected tropical diseases. The results of these screens have triggered patents and the creation of at least two spin-out companies. 

The future prospect is even more exciting. The European Lead Factory has selected, thus screened, target programmes continuously over the past years. As a consequence, only a handful of programmes have progressed to the stage where results can be disclosed at the moment. Many more results and opportunities for investment are to be expected in the upcoming years!

You can find the European Files here.